Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

37.91
-0.4000-1.04%
Post-market: 37.930.0160+0.04%19:59 EDT
Volume:21.56M
Turnover:823.15M
Market Cap:169.27B
PE:9.47
High:38.77
Open:38.05
Low:37.89
Close:38.31
52wk High:64.16
52wk Low:35.12
Shares:4.47B
Float Shares:3.19B
Volume Ratio:1.55
T/O Rate:0.68%
Dividend:1.72
Dividend Rate:4.54%
EPS(TTM):4.00
EPS(LYR):3.62
ROE:59.82%
ROA:18.73%
PB:5.20
PE(LYR):10.47

Loading ...

23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?

Options & Short Sell
·
43 mins ago

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
41 mins ago

Moderately bullish activity in Novo Nordisk with shares down 1.06%

TIPRANKS
·
3 hours ago

Novo Nordisk Opens a New Front in Cardiometabolic Care With Early-Stage Anti-Inflammatory Study

TIPRANKS
·
8 hours ago

Novo Nordisk Tests Cagrisema Switch Strategy to Strengthen Its Diabetes Franchise

TIPRANKS
·
8 hours ago

Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market

Dow Jones
·
8 hours ago

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Yesterday

Novo Nordisk announces new data on CagriSema

TIPRANKS
·
Yesterday

Patients Switching to Novo Nordisk's Wegovy Pill from Shots Lose More Weight in Real-World Study

Reuters
·
Yesterday

Novo Says Ozempic Cuts Risk of Major Cardiovascular Events

Reuters
·
Sep 29

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 29

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS
·
Sep 29

Novo Nordisk Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Eli Lilly's Mounjaro

Reuters
·
Sep 29

Novo Nordisk announces retrospective RWE on Ozempic in type 2 diabets

TIPRANKS
·
Sep 29

Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day

Dow Jones
·
Sep 29

Hengrui Pharma and Novo Nordisk Sign Licensing Agreement for HRS-1596 Project

Stock News
·
Sep 29

Option traders moderately bearish in Novo Nordisk with shares down 0.22%

TIPRANKS
·
Sep 29

Novo Nordisk A/S Series B Stock Falls Monday, Outperforms Market

Dow Jones
·
Sep 29

Taking Ozempic? a Routine Eye Exam Could Help You Understand Your Risk for Vision Loss

Dow Jones
·
Sep 28